Cascadian Therapeutics (CASC) Getting Somewhat Favorable Press Coverage, Analysis Finds
News coverage about Cascadian Therapeutics (NASDAQ:CASC) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cascadian Therapeutics earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.9005977489483 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Cascadian Therapeutics, Inc. (CASC) – Momentum Stock to Focus … – Wall Street Morning (wallstreetmorning.com)
- Advice by Analysts to Hold stock: Cascadian Therapeutics, Inc. (CASC) – Street Observer (press release) (streetobserver.com)
- Cantor Fitzgerald Remains a Hold on Cascadian Therapeutics – Analyst Ratings (analystratings.com)
- Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress – GlobeNewswire (press release) (globenewswire.com)
CASC has been the topic of a number of recent analyst reports. Barclays PLC initiated coverage on Cascadian Therapeutics in a report on Wednesday, September 6th. They set an “underweight” rating and a $4.00 price target on the stock. ValuEngine cut Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, August 9th. Zacks Investment Research cut Cascadian Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 19th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $4.00 price target on shares of Cascadian Therapeutics in a report on Thursday, August 31st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $5.63.
Shares of Cascadian Therapeutics (NASDAQ:CASC) opened at 3.53 on Wednesday. The company’s 50-day moving average price is $3.76 and its 200 day moving average price is $3.94. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.98. The company’s market cap is $178.45 million.
Cascadian Therapeutics (NASDAQ:CASC) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.06. During the same quarter last year, the business earned ($1.57) earnings per share. Equities analysts forecast that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Cascadian Therapeutics (CASC) Getting Somewhat Favorable Press Coverage, Analysis Finds” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/13/cascadian-therapeutics-casc-getting-somewhat-favorable-press-coverage-analysis-finds.html.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Stock Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related stocks with our FREE daily email newsletter.